tirzepatide and nafld Effect of Treatment on Hepatic Biomarkers in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease Type 2 Diabetes Mellitus - Arai - 2025 - Hepatology Research Pharmacotherapy for Non-alcoholic Fatty Liver

The trials used different populations, durations, and designs

Natalie Tapaskar, cardiology fellow and CardioNerds FIT Ambassador from Stanford, and faculty expert, Dr

These medicines include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and exenatide (Byetta, Bydureon), among others

Lets explore how each receptor aspect contributes to these outcomes: GLP-1 Receptor Agonist Aspect Initiates a sequence of events for better weight management Triggers glucose-stimulated insulin secretion Delays gastric emptying Suppresses glucagon secretion Results in improved weight control Promotes appetite control, aiding in weight loss GIP Receptor Agonist Aspect Enhances Tirzepatides Insulin Benefits Improves insulin sensitivity Fosters both first- and second-phase insulin secretion Leads to more robust weight control A Closer Look at Tirzepatides Clinical Success As it progresses through multiple clinical trials, Combination of GLP-1 and GIP has shown remarkable progress and achievements